Revvity (RVTY) said Monday it is launching Euroimmun's CE-marked anti-measles virus enzyme-linked immunosorbent assay 2.0, a test to diagnose measles infections or determine immunity.

The test is the first in a series that will expand Euroimmun's diagnostic portfolio, allowing the use of dried blood spots, or DBS, alongside serum and plasma. DBS testing requires only a small blood sample from a fingertip, making it easier and less invasive, especially in areas with limited medical infrastructure, the company said.

The test can be processed manually or automatically using Euroimmun's systems for DBS processing and enzyme-linked immunosorbent assay testing, Revvity said.

Price: 112.13, Change: -0.02, Percent Change: -0.02